title: Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment.
abstract: The causes of death from intranasal cowpox virus infections in mice remain unclear. Hypotheses include severe pneumonitis, hepatitis and/or hyperproduction of cytokines and chemokines. This work explores these hypotheses by studying the influence of low- and high-volume virus inocula on viral pathogenesis. BALB/c mice were infected intranasally with a syncytium-forming variant of cowpox virus in 5 microL or 50 microL volumes containing the same infectious virus challenge dose. The 50 microL infection produced a more rapidly lethal disease associated with severe pneumonitis, high lung and nasal virus titres and increased cytokine and chemokine levels in the lungs and nasal tissue, whilst liver infection was minimal. The 5 microL inoculum infection was also lethal, but the infection was primarily confined to the upper respiratory tract and included elevated nasal cytokine and chemokine levels. Levels of the pro-inflammatory cytokine interleukin-6 were particularly high in both infections. Treatment of the infections with cidofovir (100mg/kg/day for 2 days starting 24h after virus exposure) led to survival and suppression of tissue virus titres. Treatment reduced pneumonitis in the 50 microL infection and lessened cytokine hyperproduction in both infections. We conclude that a 5 microL volume inoculum of cowpox virus causes a lethal upper respiratory tract infection, whilst the 50 microL inoculum targets both upper and lower respiratory tracts, with excessive release of systemic pro-inflammatory factors. Cidofovir effectively treated both infections and slowed viral replication sufficiently to subdue the exaggerated release of pro-inflammatory mediators.
authors.affiliation: Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT 84322, USA. dsmee@cc.usu.edu
authors.forename: Donald F
authors.initials: DF
authors.lastname: Smee
authors.forename: Brian B
authors.initials: BB
authors.lastname: Gowen
authors.forename: Miles K
authors.initials: MK
authors.lastname: Wandersee
authors.forename: Min-Hui
authors.initials: MH
authors.lastname: Wong
authors.forename: Ramona T
authors.initials: RT
authors.lastname: Skirpstunas
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Baldwin
authors.forename: Justin D
authors.initials: JD
authors.lastname: Hoopes
authors.forename: Robert W
authors.initials: RW
authors.lastname: Sidwell
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000502:physiology; D018925:Chemokines / Q000378:metabolism; D000077404:Cidofovir; D015605:Cowpox / Q000188:drug therapy* / Q000473:pathology* / Q000821:virology; D015608:Cowpox virus; D016207:Cytokines / Q000378:metabolism; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D015726:Giant Cells / Q000821:virology; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size; D063065:Organophosphonates / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D018925:Chemokines; D016207:Cytokines; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir